1. Home
  2. GNPX vs CNSP Comparison

GNPX vs CNSP Comparison

Compare GNPX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • CNSP
  • Stock Information
  • Founded
  • GNPX 2009
  • CNSP 2017
  • Country
  • GNPX United States
  • CNSP United States
  • Employees
  • GNPX N/A
  • CNSP N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • CNSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNPX Health Care
  • CNSP Health Care
  • Exchange
  • GNPX Nasdaq
  • CNSP Nasdaq
  • Market Cap
  • GNPX 6.1M
  • CNSP 5.6M
  • IPO Year
  • GNPX 2018
  • CNSP 2019
  • Fundamental
  • Price
  • GNPX $0.38
  • CNSP $1.15
  • Analyst Decision
  • GNPX Strong Buy
  • CNSP Hold
  • Analyst Count
  • GNPX 1
  • CNSP 1
  • Target Price
  • GNPX $10.00
  • CNSP N/A
  • AVG Volume (30 Days)
  • GNPX 6.0M
  • CNSP 332.7K
  • Earning Date
  • GNPX 05-13-2025
  • CNSP 05-14-2025
  • Dividend Yield
  • GNPX N/A
  • CNSP N/A
  • EPS Growth
  • GNPX N/A
  • CNSP N/A
  • EPS
  • GNPX N/A
  • CNSP N/A
  • Revenue
  • GNPX N/A
  • CNSP N/A
  • Revenue This Year
  • GNPX N/A
  • CNSP N/A
  • Revenue Next Year
  • GNPX N/A
  • CNSP N/A
  • P/E Ratio
  • GNPX N/A
  • CNSP N/A
  • Revenue Growth
  • GNPX N/A
  • CNSP N/A
  • 52 Week Low
  • GNPX $0.22
  • CNSP $1.21
  • 52 Week High
  • GNPX $4.09
  • CNSP $800.00
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 43.09
  • CNSP 29.50
  • Support Level
  • GNPX $0.22
  • CNSP $1.28
  • Resistance Level
  • GNPX $0.39
  • CNSP $1.46
  • Average True Range (ATR)
  • GNPX 0.06
  • CNSP 0.34
  • MACD
  • GNPX 0.00
  • CNSP -0.11
  • Stochastic Oscillator
  • GNPX 31.23
  • CNSP 0.84

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Share on Social Networks: